[Ip-health] Working Group on Sustainable Development Goals
mppinheiro at hotmail.com
Mon Mar 31 07:09:14 PDT 2014
The Open Working Group on Sustainable
Development Goals meets in New York this week for its 10th session.
Watch live today at 10 am EDT via http://webtv.un.org/
Get all the details on the meeting from the UN Sustainable Development Knowledge Platform here: http://bit.ly/OWG10
> Date: Thu, 27 Mar 2014 17:07:30 +0100
> From: thiru at keionline.org
> To: Ip-health at lists.keionline.org
> Subject: [Ip-health] Pecoul & Balasegaram in Nature - WHO: Steering plans for neglected diseases
> NATURE | CORRESPONDENCE
> WHO: Steering plans for neglected diseases
> Bernard Pécoul & Manica Balasegaram
> Nature 507, 431 (27 March 2014)
> doi: 10.1038/507431d
> Published online 26 March 2014
> Mary Moran criticizes plans by the World Health Organization (WHO)
> for tackling neglected diseases in the developing world (Nature 506,
> 267; 2014). Her arguments are misleading and trivialize global efforts to
> fix the research and development (R&D) system that is failing to address
> the health needs of people in these countries.
> After 10 years' effort by WHO member states, the WHO Consultative
> Expert Working Group on R&D Financing and Coordination has proposed a
> framework to tackle these R&D shortcomings. This aims to promote and
> needs-driven innovation, sustainable funding mechanisms and patient
> access to health technologies.
> Moran contends that the current drug pipeline for neglected diseases
> is "successful". In the past ten years, however, only 4% of all new drugs
> and vaccines and 1% of all new chemical entities were for neglected
> diseases -- and none was suitable for the 17 neglected tropical diseases (B.
> Pedrique et al. Lancet Glob. Health 1, e371-e379; 2013). Increased funding
> and better coordination will help, but what is really needed is a
> greater global incentive for needs-driven R&D.
> To fulfil the working group's criteria, the WHO pilot projects need
> better coordination, optimization of research and accelerated delivery of
> tools. This will be achieved only by strengthening capacity,
> testing innovative or pooled financing, developing an open-knowledge
> approach, and unlinking R&D costs from the end price of products.
> Drugs for Neglected Diseases initiative, Geneva, Switzerland.
> Bernard Pécoul
> Médecins Sans Frontières, Geneva, Switzerland.
> Manica Balasegaram
> Ip-health mailing list
> Ip-health at lists.keionline.org
More information about the Ip-health